Focus: Tangram Therapeutics is a UK-based biotech company specializing in in-silico drug discovery, leveraging computational approaches to identify novel therapeutics. The company is in early-stage development with a single Phase 1/2 program.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Tangram is a high-risk, early-stage computational biotech with limited external visibility—suitable only for risk-tolerant technologists betting on in-silico platform validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tangram Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tangram Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles